October 2024
FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Approval
Stealth BioTherapeutics, ultra-rare disease, FDA approval, Barth syndrome, elamipretide
AstraZeneca’s Airsupra Asthma Trial Halted Early Due to Overwhelming Efficacy, Paving Way for Regulatory Submission
AstraZeneca, Airsupra, asthma treatment, clinical trial, overwhelming efficacy, regulatory submission
Kaleo Announces 58 Layoffs Despite Recent Expansion Plans for EpiPen Rival Auvi-Q
Kaleo layoffs, Auvi-Q, EpiPen competitor, pharmaceutical industry, job cuts, Richmond-based company
Astellas Launches First Direct-to-Consumer Campaign for IZERVAY, Highlighting Its Potential to Slow Geographic Atrophy Progression
IZERVAY, geographic atrophy, age-related macular degeneration, direct-to-consumer campaign, Astellas Pharma
Astellas Expands Gene Therapy Portfolio with $2.2 Billion Deal for AviadoBio’s Frontotemporal Dementia Treatment
Astellas Pharma Inc., AviadoBio Ltd., Gene Therapy, Frontotemporal Dementia, FTD-GRN, AVB-101, Progranulin Mutations, Neurodegenerative Diseases
Sage Therapeutics’ Dalzanemdor Fails in Alzheimer’s, Hopes Now Rest on Huntington’s Disease Trial
Sage Therapeutics, Dalzanemdor, Alzheimer’s Disease, Huntington’s Disease, Clinical Trials, Neurodegenerative Disorders
Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases
Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement
GEMMABio Secures $100M Partnership to Advance Rare Disease Gene Therapies in Brazil
GEMMABio, gene therapy, Brazil, rare diseases, $100M partnership, health ministry
RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup
RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup
Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation
Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study